Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiveTreg
2023-508261-32-00Phase 2Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Feb 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TREG02, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Primary safety endpoint 1, Primary safety endpoint 2 and 1 more. Planned start Feb 2025; status: authorised.
02
Drugs
TREG02
Beyond the preview
Go deeper on 2023-508261-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508261-32-00.